Broad claim construction leads to invalidity of Novartis's patent for EXELON Alzheimer's patch

Moore, Sebastian; Pead, Grace
September 2015
Journal of Intellectual Property Law & Practice;Sep2015, Vol. 10 Issue 9, p653
Academic Journal
The article discusses the court case Novartis AG & Others versus Focus Pharmaceuticals Ltd. & Others wherein the Patents Court of England and Wales ruled on April 27, 2015 that the patent of Novartis covering its EXELON rivastigmine transdermal patch to treat Alzheimer's disease is invalid.


Related Articles

  • Novartis Loses Discrimination Suit.  // Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p9 

    The article reports on the decision of the federal jury in New York regarding the gender discrimination lawsuit against Novartis AG.

  • Gleevec loses Indian patent battle. Jayaraman, Killugudi // Nature Biotechnology;May2013, Vol. 31 Issue 5, p371 

    The article presents a court case wherein the Supreme Court in India has rejected the extension of patent protection filed by Novartis for its leukemia drug Gleevec or Glivec (imatinib).

  • Big win for generic players.  // Business & Economy;May2013, Vol. 8 Issue 5, p20 

    The article reports on the dismissal of a plea brought by Swiss pharmaceutical company Novartis AG for attempting to patent an updated version of a prohibitively expensive cancer drug by the Supreme Court of India.

  • NOVARTIS. Investor's Business Daily // Investors Business Daily;1/ 9/2014, pA02 

    The article reports on the lawsuit filed against the Swiss drugmaker Novartis by the New York attorney general over alleged kickbacks to lift sales of Exjade, its iron-reduction drug.

  • A bas le mais! P.S. // Earth Island Journal;Spring98, Vol. 13 Issue 2, p10 

    Reports that 120 members of the French Peasant Confederation took direct action against Novartis, an agrochemical producer, seed producer and pharmaceutical company in France. Details on the action taken; Arrests which were made.

  • Balancing Competing Loyalties. Sytch, Maxim; Uribe, Jose; Kim, Yong H. // Harvard Business Review Digital Articles;2/3/2020, p2 

    No abstract available.

  • CIAs pressure pharma to rethink rep compensation. Comer, Ben // Medical Marketing & Media;Nov2010, Vol. 45 Issue 11, p8 

    The article reports on the Corporate Integrity Agreement (CIA) signed by the Novartis during its settlement with the U.S. Department of Justice involving the need for the Swiss-based manufacturer to rethink about the incentive compensation for medical representatives.

  • Intellectual Property Battles in Solid-State Chemistry. Van Arnum, Patricia // Pharmaceutical Technology;May2013, Vol. 37 Issue 5, p54 

    The article discusses the India's Supreme Court case Novartis AG vs. Union of India. The case highlights various issues of patent strategies for solid forms research and characterization raised from the rejection of imatinib mesylatere drug manufactured from Novartis AG. The case further informs...

  • Novartis Faces Sex Discrimination Lawsuit.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p8 

    The article reports on the gender discrimination class-action lawsuit filed by 5,600 women sales representatives against Novartis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics